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AMPA receptors are glutamate-gated 
cation channels assembled from GluA1-4 
subunits and have properties that are strongly 
dependent on the subunit composition. The 
subunits have different propensities to form 
homomeric or various heteromeric receptors 
expressed on cell surface, but the underlying 
mechanisms are still poorly understood. Here, 
we examined the biochemical basis for the poor 
ability of GluA3 subunits to form homomeric 
receptors, linked previously to two amino acid 
residues, Y454 and R461, in its ligand-binding 
domain (LBD). Surface expression of GluA3 
was improved by co-assembly with GluA2 but 
not with stargazin, a trafficking chaperone and 
modulator of AMPA receptors. The secretion 
efficiency of GluA2 and GluA3 LBDs paralleled 
the transport difference between the respective 
full-length receptors and was similarly 
dependent on Y454/R461, but not on LBD 
stability. In comparison to GluA2, GluA3 
homomeric receptors showed a strong and 
Y454/R461-dependent tendency to aggregate 
both in the macroscopic scale measured as 
lower solubility in nonionic detergent and in the 
microscopic scale evident as the preponderance 
of hydrodynamically large structures  in  
density gradient centrifugation and native gel 
electrophoresis. We conclude that the impaired 
surface expression of homomeric GluA3 
receptors is caused by nonproductive assembly 
and aggregation to which LBD residues Y454 
and R461 strongly contribute. This aggregation 
inhibits the entry of newly synthesized GluA3 
receptors to the secretory pathway.                      
 
α-Amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors are 
tetrameric ligand-gated ion channels which 
mediate fast excitatory neurotransmission in 
vertebrate brain (1,2). The functional properties of 
AMPA receptors, including channel kinetics, ion 
permeability, ligand pharmacology and regulation, 
are determined by the subunit composition. AMPA 
receptors are built from four subunit types (GluA1-
4), each expressed as multiple alternatively spliced 
and/or RNA-edited variants. Studies with native 
and recombinant receptors indicate that receptor 
assembly is not random but strongly favors certain 
subunit combinations (3,4). The majority of native 
AMPA receptors are heteromers of edited GluA2 
subunits with GluA1 or GluA3 subunits, forming 
channels which are impermeable to Ca2+ and 
showing a linear current-voltage (I-V) relation 
(3,5,6). Minor native populations of homomeric 
AMPA receptors are formed by GluA1 or GluA4 
subunits to produce inwardly rectifying and Ca2+-
permeable channels (7,8). 
At present, the molecular logic underlying the 
formation and cellular processing of specific 
subunit assemblies in AMPA receptors is still 
poorly understood.  The oligomerization is 
initiated by formation of dimers between N-
terminal domains (NTD) of nascent receptor 
polypeptides in the endoplasmic reticulum (ER), 
followed by interactions involving the 
transmembrane segments and the ligand-binding 
domains (LBD) (9-11). The relative strength of 
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NTD contacts can partly explain the strong 
preference of certain subunits like GluA3 for 
heteromeric assembly, but also the LBD harbors 
important structural determinants which control the 
biogenesis of AMPA receptors in a subunit or 
subunit variant –dependent manner (12-14). In 
addition, auxiliary proteins, including 
transmembrane AMPA receptor-associated 
proteins (TARP) and cornichon homologs, 
associate with AMPA receptors already in the ER 
and, in principle,  may influence the assembly 
process (9,15-17). 
Recently, we demonstrated that two LBD 
residues, Y454 and R461, are responsible for the 
poor delivery of homomeric GluA3 receptors to 
cell surface both in the presence and absence of 
NTD (12). These residues are not directly engaged 
in glutamate binding nor in subunit interactions, 
and the reason why they inhibit the formation or 
transport of homomeric GluA3 to the cell surface 
is unclear. Here, we performed a comparative 
biochemical analysis of wild-type and mutated 
GluA2 and GluA3 receptors expressed in HEK293 
cells. We found that GluA3 receptors exhibit 
aberrant, Y454/R461-dependent tendency to 
disturbed oligomerization and aggregation. Our 
findings suggest that subunit-dependent balance 
between transport-competent oligomers and 
higher-order abnormal assemblies contributes to 
the preferences of AMPA receptor subunits for 
homomeric or heteromeric expression.  
 
EXPERIMENTAL PROCEDURES    
DNA constructs - All cDNAs encoding 
full-length AMPA receptor subunits or mutants 
thereof represented the rat AMPA receptor 
subunits; the flip/flop isoform is indicated in the 
text and figure legends; GluA2 is the edited 
(Q607R) form. All were expressed with an N-
terminal signal sequence and tag from pcDNA3.1 
(Stratagene)  (12,13,18). Plasmids encoding human 
stargazin and rat GluN1 (NR1) were kind gifts 
from John L. Black III (Mayo Medical School, 
Rochester, MN), and Dr Rolf Sprengel (Max 
Planck Institute for Medical Research, Heidelberg, 
Germany), respectively. Mammalian expression  
constructs of GluA2 and GluA3 LBDs were built 
on pEGF-C1 (Clontech) by replacing the GFP 
encoding sequence by a cDNA expression cassette 
encoding an N-terminal signal peptide, Flag-
epitope, requisite GluA sequences and C-terminal 
Myc-tag as described before for GluA4 (13). 
Bacterial expression constructs were created by 
PCR-based cloning and inserted into T7 promoter 
containing  vector and a C-terminal 6xHis tag. The 
constructs were designed to correspond to AMPA 
receptor ligand-binding domains used for 
crystallization studies (19,20). All constructs were 
verified by restriction mapping and sequencing of 
PCR amplified regions.   
Antibodies - For immunoblotting, the 
following antibodies were used: mouse 
monoclonal anti-Flag M1 (1 µg/ml; Sigma F-
3040), anti-GAPDH (0.03 µg/ml; Sigma G-8795), 
and anti-GFP (1:1000; Sigma G6539), rabbit 
polyclonal anti-Myc (0.2 µg/ml; AbCam ab9106), 
anti-GluA2/3 IgG (1 µg/ml; Millipore #07-598), 
anti-GluN1 (0.2 µg/ml; Chemicon AB1516), anti-
GRP78 (Sigma G-8918; 1:2000), and anti-
stargazin serum (1:2000; Ref.13);   horseradish 
peroxidase -conjugated anti-mouse (1:3000; 
NA931V) or anti-rabbit (1:3000; NA934V) IgGs, 
both from GE Healthcare, were used as secondary 
antibodies. For  immunoprecipitation, mouse 
monoclonal  anti-Flag M2 (2 µg/ml; Sigma F-
3165) or anti-Myc (5 µg/ml; 9E10) were used.  
Cell culture and transfection - HEK293 
cells were cultured in DMEM supplemented with 
10 % (v/v) fetal calf serum and penicillin-
streptomycin, and transfected with appropriate 
plasmids by using calcium phosphate 
coprecipitation as previously described (21). For 
patch-clamp experiments, pEGFP1-C1 (Clontech) 
was co-transfected for the visualization of 
transfected cells. For some experiments, cells were 
incubated with tunicamycin (2 µg/ml; Sigma T-
7765) for 24 hours prior to harvesting. 
Electrophysiology – Whole-cell patch 
clamp recordings and analysis of glutamate-
triggered currents in transfected cells were carried 
out as previously described (22). In brief, 
recordings from AMPA receptors expressing 
HEK293 cells were done at holding potential of  
-60 mV. L-glutamate was diluted in external 
recording solution containing 150 mM NaCl, 2.5 
mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 10 mM 
glucose and 10 mM HEPES (pH 7.4; 320 mOsm) 
and applied to cells using a piezo driven applicator 
(Siskiyou Piezo Switcher; Siskiyou Corporation, 
OR, USA). Electrodes had resistance of 2-4 MΩ 
when filled with internal solution containing 140 
mM CsCl, 2 mM MgCl2, 10 mM EGTA and 10 
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mM HEPES (pH 7.2, 315 mOsm). Cells were 
lifted from the bottom of culture dish by the patch 
clamp pipette to facilitate the solution exchange. 
Each drug application was done twice and traces 
were averaged for analysis. 
Fluorescence microscopy - Representative 
micrographs of GluA3-GFP expressing HEK293 
cells were acquired via an EVOS fl digital inverted 
microscope (AMG, Life Technologies) with GFP 
LED light cube (570 nm excitation, 525 nm 
emission) and 20x objective. 
  Biochemical Analyses – Transfected cells 
were extracted in TNE buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 5 mM EDTA) containing 
1% (w/v) Triton X-100, followed by 
ultracentrifugation at 100,000 x g for 1 h. 
Detergent-soluble and non-soluble receptor 
fractions were determined from the 
immunoreactivity present in the supernatant and in 
the pellet, respectively. They were quantitated as 
described below. Protein concentrations were 
determined by bicinchonic acid assay (Uptima, 
Interchim, France) using bovine serum albumin as 
standard. Immunoprecipitation, cell surface 
biotinylation and analysis of the secretion of ligand 
binding domain were performed as described 
previously (13,21,23).  
Cell surface biotinylation was done as described 
(13). Briefly, transfected HEK293 cells were 
rinsed with PBS containing 1 mM CaCl2, 0.5mM 
KCl, 2.5 mM MgCl2, and incubated with EZ-Link 
sulfo-NHS-SS-Biotin (Pierce) at 0.5 mg/ml in the 
above buffer for 30 min at room temperature. Non-
reacted reagent was removed by washing cells with 
the above buffer. Triton X-100 extracts were made 
as described above and subject to streptavidin- 
Sepharose precipitation (GE Healthcare). 
Immunoprecipitation was done as described (21). 
Briefly, Triton X-100 extracts of transfected cells 
were incubated with pre-washed Gamma-bind 
Sepharose (GE Healthcare) and appropriate 
antibody (at concentration detailed above) and 
mixed for 2 h at 4 °C. 
Secretion of GluA2 and GluA3 LBDs was GluA 
S1S2 construct secretion was analyzed as 
described (23). Briefly, growth media was 
collected from transfected HEK293 cells 40 h after 
transfection, and 1 mM PMSF was added. Cell 
debris was pelleted by centrifugation (1500 g, 5 
min, 4°C). The total cell extracts were prepared as 
above.  
Density gradient centrifugation – 
Gradients were prepared by layering 10% (w/v) 
sucrose in TNE buffer containing 0.5 % Triton X-
100 over 40% (w/v) sucrose solution (1:1 ratio) 
and incubating horizontally for 75 min at room 
temperature. Thus prepared gradients were stored 
vertically at 4 °C until use. Transfected HEK293 
cell extracts (300 µl) were layered on top of the 
gradients which were run in pairs in ultracentifuge 
with Sw-55Ti rotor (Beckman-Coulter) at 175,000 
x g for 16 h at +4 °C. Fractions (200 µl) were 
collected from the bottom of centrifuge tube by 
using peristaltic pump (Pharmacia Biotech P-1). 
Gel electrophoresis analysis – Samples 
were run on either Lonza 4-12% or Bio-Rad 4-
15% TGX Criterion gradient gels for both 
denaturing (SDS) or Blue Native (BN)-
polyacrylamide gel electrophoresis (PAGE). For 
SDS-PAGE samples were prepared in Laemmli 
sample buffer (with final concentration of 60 mM 
Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5% β-
mercaptoethanol, 12.5 mM EDTA 0.01% 
bromophenol blue). BN-PAGE was run according 
to the protocol of Gill et al. (24) and samples were 
prepared in native loading buffer (with final 
concentration of 60 mM Tris-Cl pH 6.8, 10% 
glycerol, 0.01% bromophenol blue); molecular 
standards were indicated by Native Mark (Novex, 
Life Technologies). Following gel separation, 
proteins were transferred onto Hybond membrane 
(GE Healthcare) and immunoblotted. The samples 
used for BN-PAGE were obtained from the 
sucrose density gradients with the exception of the  
analysis of crude cell extracts. In the latter case, 
Triton X-100 extracts prepared from transfected 
cells were cleared by centrifugation at 12,000 x g 
for 20 min, mixed with native loading buffer and 
used for electrophoresis.  
Immunoblotting and analysis – For 
immunoblotting, ClarityTM Western ECL substrate 
(Bio-Rad, 170-5061) was used. ECL signal was 
detected and measured either by ChemiDoc XRS 
system and Quantity One software (BioRad) or by 
BioSpectrum 810 and VisionWorksLS software 
(Ultra-Violet Products Ltd, UK). The pixel density 
of the immunoreactive bands was obtained from 
the longest possible exposure prior to saturation of 
signal. If required the relative expression levels 
were normalised to a control, as defined in the 
respective figure legend. For determination of 
percentage of  oligomeric state following BN-
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PAGE, the signal was summed from boxes 
corresponding to aggregate, tetramer, dimer and 
monomer for all fractions run (see Figure 7A 
middle panel). An equivalent box for background 
only was also measured, if this corresponded to 5 
% or more of total signal the experiment was 
discarded.  
Bacterial protein expression and 
purification – 6xHis-tagged proteins were 
expressed and purified according to standard 
procedures as described previously (25) with the 
following modifications; the plasmids containing 
wild type or point-mutated GluA2i S1S2 and 
GluA3i S1S2 segments were transformed into E. 
coli Origami (DE3)pLysS for protein expression. 
The first round of purification from E. coli lysates 
was made via Ni-NTA agarose (Qiagen) against 
the 6xHis-tag. The proteins eluted from Ni-NTA 
agarose were dialyzed against 20 mM Tris-HCl, 
pH 8.0 buffer and then loaded on to a DEAE 
column (DEAE-Sepharose CL-6B, Pharmacia). 
Following washing proteins were eluted with 20 
mM Tris-HCl pH 8.0 buffer containing 0.1 M 
NaCl. All purified proteins were concentrated by 
centrifugal devices (microsep 30K, Pall) to 
approximately 2 mg/ml and stored in elution buffer 
solution at 4oC.   
Chemical denaturation – Aliquots of 
bacterially expressed and purified GluA2 or GluA3 
LBD proteins were incubated with increasing 
concentrations of urea (0-8 M) in the presence or 
absence of 10 mM L-glutamate. Intrinsic 
fluorescence at 300-450 nm region produced by 
excitation at 295 ± 5 nm was measured in quartz 
cuvettes (Hellma) using a FluoroMax-4 
spectrofluorometer (Horiba Scientific), and 
analyzed by Origin 7.5 software. For calculation of 
the urea denaturation curves peak emission 
intensities at 325 nm and 327 nm were used for for 
GluA2 and GluA3 LBDs, respectively. 
Fluorescence intensity was plotted against urea 
concentration and individually best-fit with 
sigmoidal dose-response (variable slope and no 
constraints) model in in GraphPad Prism v4 
(GraphPad Software Ltd).  
Circular dichroism (CD) spectroscopy – 
For CD spectroscopy protein samples were 
dialyzed overnight against sodium phosphate 
buffer (50 mM sodium phosphate pH 7.4), 
followed by centrifugation (5 min, 13,000 rpm, 
4°C). Thermal stability of the GluA2i, GluA3i and 
GluA3i (Y454A/R461G) LBDs was monitored by 
CD-spectroscopy using a Jasco J-720 
spectropolarimeter. Thermal denaturation scans 
were recorded using a 0.1 cm cuvette, wavelength 
195 nm,  a temperature range from 20°C to 70°C 
with temperature steps of 0.1°C. The protein 
concentration was 0.2 mg/ml. CD-spectra were 
measured in presence and absence of L-Glutamate 
at 1 mM for GluA3i and GluA3i (Y454A/R461G) 
and 0.5 mM for GluA2i. Data was compiled in 
Excel (Microsoft Office 2007). The spectra were 
plotted and Tm calculated with GraphPad Prism v4 
(GraphPad Software Ltd). 
Statistical Analysis – Data are presented as 
mean ± SEM, unless otherwise stated and 
described, where n is the number of independent 
experiments. Analysis was by Student’s t-test or by 
one or two-way ANOVA followed by Bonferroni’s 
multiple comparison test or by Dunnett’s multiple 
comparison test to control. Statistical significance 
of p values was indicated by asterisks as follows: * 
p <0.05; ** p <0.01; *** p <0.001. All statistical 
analyses were done by using GraphPad Prism. 
Analysis of desensitization kinetics of patch clamp 
recordings were done by Clampfit 10.2 software 
(Molecular devices, Sunnyvale CA, USA) using 
single exponential fit paradigm. 
 
RESULTS  
Surface expression of GluA3 is rescued 
by co-assembly with GluA2 but not by association 
with stargazin. Previously, we showed that co-
expression with GluA2-flip (GluA2i) promotes the 
surface expression of the otherwise mostly 
intracellularly retained GluA3i in transfected 
HEK293 cells (12). We now analyzed the ability of 
GluA2 isoforms, flip and flop (GluA2o) and of the 
GluA2i point mutant GluA2i A451Y/G458R 
(GluA2i AG/YR) to promote GluA3i surface 
expression as determined by biotinylation assay. 
Biotinylation with the cell-impermeant biotin 
derivative interferes with immunoreactivity of 
extracellular epitopes so a GFP tag was introduced 
to the C-terminus of the receptor polypeptide. This 
C-terminal fusion does not alter the basic 
trafficking of GluA2 and GluA3 as GluA2i-GFP 
showed significant surface expression, whereas 
only a minor fraction of Glu3i-GFP was present on 
the plasma membrane (Fig. 1A). Thus, GluA3i-
GFP was expressed in HEK293 cells together with 
the Flag-tagged test constructs GluA3i (control), 
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GluA2i, GluA2o, or GluA2i(AG/YR). After 
surface biotinylation and streptavidin pulldown, 
GluA3i-GFP was visualized by immunoblotting 
(Fig. 1, B and C). Consistent with earlier findings, 
heteromeric assembly improved the surface 
expression of the GluA3i: in the presence of 
GluA2i, plasma membrane levels of GluA3i-GFP 
increased six-fold. Co-expression with the flop 
isoform of GluA2 and with the AG/YR double 
mutants which carry the two residues responsible 
for the intracellular retention of GluA3, did not the 
increase surface expression of GluA3i-GFP in a 
statistically significant manner (Fig. 1C). In order 
to determine whether GluA3 displays significant 
preference for heteromeric over homomeric 
assembly, N-terminally tagged GluA2i and GluA3i 
were expressed with a differently tagged version of 
the same or the other subunit, and subjected to 
immunoprecipitation. Flag-tagged GluA3i was co-
immunoprecipitated with myc-tagged GluA3i or 
GluA2i and vice-versa to similar extent. Thus, 
suggesting that under the experimental conditions 
of transient expression in HEK293 cells GluA3  
has no significant preference for heteromeric 
assembly (Fig. 1D). 
In addition to co-assembly, association 
with auxiliary proteins is known to promote 
surface expression of AMPA receptors. Therefore, 
we studied whether co-expression with stargazin (a 
prototype member of transmembrane AMPA 
receptor regulatory proteins) would promote the 
trafficking of GluA3 to the plasma membrane. 
Previously, we have shown that stargazin rescues 
the otherwise poor surface expression of the flop 
variants of GluA1 and GluA4 homomers (13). 
However, despite strong expression and surface 
location of stargazin no significant improvement 
was seen for GluA3 (Fig. 2, A and B). Due to this 
unexpected result, it was important to verify the 
association of stargazin with GluA3. Co-
immunoprecipitation experiments did not show 
statistically significant difference in stargazin 
association between GluA3 and GluA2 (Fig. 2C). 
Whole cell patch clamp electrophysiology on 
transfected HEK293 cells did not show a 
statistically significant increase in the maximal 
whole-cell currents in the presence of stargazin, 
(Fig. 2D). However, when stargazin was co-
expressed the desensitization of glutamate 
responses was significantly slower: time-constants 
(τdes values)  for the onset of desensitization were 
10.48 ms ± 1.11 for GluA3+Stg and 4.50 ms ± 
0.38 GluA3 for GluA3 alone, indicating functional 
association of stargazin with GluA3 (Fig. 2E). 
Differences in LBD stability do not 
explain the poor trafficking of GluA3. Ligand-
binding domains of GluA2 and GluA3, expressed 
as soluble secretable fusion proteins, reproduce the 
trafficking difference between the subunits (12). It 
is not clear, however, whether the underlying 
mechanisms are shared. In order to resolve this 
question we analyzed whether the two amino acid 
differences in LBD, which explain the differing 
surface expression levels of intact GluA2 and 
GluA3, can similarly affect the secretion of LBDs. 
Epitope-tagged LBD constructs were  expressed in 
HEK293 cells and LBD protein levels were 
determined in the cells and culture medium by 
Western blotting (Fig. 3, A and B). In agreement 
with earlier results, wild-type GluA2 LBD was 
well secreted from the cells, whereas GluA3 LBD 
was not. Importantly, the double mutants 
GluA3(YR/AG) and GluA2(AG/YR) reversed the 
behavior and showed secretion patterns typical for 
the other subunit:  GluA3(YR/AG) LBD was 
secreted efficiently to the culture medium, wheras 
GluA2(AG/YR) LBD was largely retained in the 
cells (Fig. 3, B and C). All LBD constructs were 
equally well expressed within the cells (Fig. 3B,  
left panels).  
The above results suggest that similar 
mechanisms contribute to the transport defects of 
full-length GluA3 and GluA3 LBD. One obvious 
possibility is that GluA3 LBD is less stable and 
because of local unfolding GluA3 or GluA3 LBD 
would not be able to pass the quality control of the 
secretory pathway. To produce sufficient protein 
for the measurement of the conformational 
stability, we engineered the LBD constructs for 
expression in E. coli. The LBDs contain one 
essential disulfide bond so E.coli strain Origami, 
which harbors oxidizing cytosol, was used as the 
expression host. Initial attempts to express LBDs 
which had an overall design as shown in Figure 
3A, but lacking the signal peptide, failed to 
produce any significant levels of protein. 
Therefore, the LBDs were redesigned to 
correspond to the GluA2 S1S2J construct (19) that 
has been used in a similar expression system to 
produce GluA2 and GluA3 LBDs for 
crystallization (20) (Fig. 4A). This approach led to 
successful expression of both LBDs as soluble 
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proteins (although GluA3 yields were consistently 
lower) and the proteins were purified by using 
metal-chelation affinity chromatography. Stability 
was assessed by measuring the intrinsic tryptophan 
fluorescence in increasing concentrations of urea 
in the presence and absence of L-glutamate (10 
mM). Typical plots of fluorescence intensity 
against urea concentration are shown in Figure 4B; 
they were sigmoidal and showed a marked shift to 
the right (to higher urea concentrations) in the 
presence of glutamate, indicative of co-operative 
unfolding and stabilization by glutamate (Fig. 4B): 
The EC50 values for urea-induced unfolding are 
given (Fig. 4C and Table 1). Interestingly, GluA3 
appeared more stable than GluA2, effectively 
ruling out poor folding of GluA3 LBD as an 
explanatory factor of the transport defect. To 
verify the results from chemically-induced 
unfolding we analyzed the thermostability of 
GluA2 and GluA3 LBDs by circular dichroism 
(CD) spectroscopy. Consistent with the results 
from chemically-induced denaturation the GluA3 
LBD was more stable for thermally triggered 
unfolding (Fig. 4D). The presence of L-glutamate 
provided substantial stabilization for both LBDs, 
the Tm values increased by over ten degrees 
Celsius for both GluA2 and GluA3 LBDs (Fig. 4D 
and Table 1). Interestingly, the thermostability of 
the LBD mutant GluA3 (YR/AG), which reverses 
the trafficking phenotype to GluA2-like, showed 
similar stability as the GluA3 wild-type both in 
presence and absence of L-Glutamate (Fig. 4D and 
Table 1. The results indicate that the differences 
between GluA2 and GluA3 in LBD stability and in 
the transport can be separated. Thus, stability and 
transport competency are  likely independent from 
each other.  
Homomeric GluA3 receptors have a 
tendency for abnormal oligomerization and 
aggregation. In order to identify possible gross 
differences in the biochemical properties of GluA2 
and GluA3, we determined the detergent-solubility 
of homomeric GluA2 and GluA3 receptors 
expressed in HEK293 cells. For this purpose, 
Triton X-100 –soluble and insoluble fractions were 
separated by ultracentrifugation and analyzed by 
SDS-PAGE and immunoblotting (Fig. 5A). There 
was a substantial difference between the subunits: 
70 % of GluA2 protein (determined by using anti-
Flag antibody) was solubilized by Triton X-100, 
whereas the fraction of detergent-soluble GluA3 
was only half of that (Fig. 5, A and B). If the poor 
solubility of GluA3i is due to aggregation, it is 
possible that it could increase aggregation of other 
proteins coexpressed with it. To test this, we 
studied the detergent solubility of the GluN1 
subunit of the NMDA receptor when coexpressed 
with either GluA3i or with GFP. Expression with 
GluA3i led to a significant increase in the amount 
of insoluble GluN1 (Fig. 5, C and D), supporting 
aggregation as an explanation for the poor 
detergent-solubility of GluA3i homomers. To find 
out whether the detergent-solubility is related to 
the trafficking phenotypes, the detergent-soluble 
fractions of wild-type and the reciprocal double 
mutated GluA2 and GluA3 flip and flop receptors 
were analyzed in parallel and normalized to 
GAPDH (serving as a loading standard for cellular 
protein). For both flip (Fig. 5, E and F) and flop 
(Fig. 5, G and H) isoforms, the  point mutations 
completely reversed the solubility properties of the 
parental receptors; GluA3 YR/AG behaved like 
wild-type GluA2 and GluA2 AG/YR showing 
GluA3-like low detergent-solubility. Next, we 
examined the effects of expression of GluA2i and 
GluA3i on GRP78, an indicator of stress in the 
endoplasmic reticulum. In comparison to mock-
transfected cells, the amount of GRP78 protein 
was slightly elevated in cells expressing GluA2i 
and GluA3i, but there was not difference between 
the subunits (Fig. 5I). In contrast, GRP78 level was 
strongly increased in tunicamycin-treated cells (2 
µg/ml; 24 hours), used as a positive control. Anti-
Flag immunoprecipitations showed that GRP78 is 
associated with both subunits to the same extent 
(Fig. 5J).  
The above-described results suggest that 
while the crucial difference between GluA2 and 
GluA3 homomeric receptors is strictly related to 
specific LBD residues, the mechanistic explanation 
for the different transport competences of GluA2 
and GluA3 receptors does not lie in the primary 
folding of the LBD, but more likely in the solution 
behavior of the cognate receptors. This prompted 
us to analyze the oligomeric state of GluA2, 
GluA3 and GluA3 (YR/AG) receptors by using 
fractionation of  detergent-soluble receptors in 
sucrose density gradient centrifugation. Anti-Flag 
immunoblots of sucrose gradient fractions showed 
remarkable differences between the receptor 
variants (Fig. 6A). The majority of GluA3 110-kDa 
signal was associated with the higher density 
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sucrose fractions with a broad peak (P1) at 
fractions 5-7 with substantial immunoreactivity 
also present at the bottom of the gradient, likely 
representing aggregation (Fig. 6B). A minor 
population of GluA3 sedimented at a lower speed 
forming a distinct peak at fractions 13-14 (P2). In 
contrast, most of GluA2 sedimented in a uniform 
manner producing a peak coinciding with P2. A 
minor fraction of GluA2 was present in the higher 
density fractions. The mutant GluA3 YR/AG 
showed intermediate behavior distributing equally 
between the two peaks P1 and P2, but was also 
present in the fractions between these peaks (Fig. 
6B). In addition to the 110-kDa receptor subunit 
monomer band a diffuse ~250-kDa band was 
prominently present in the peak fractions of GluA2 
and GluA3, in amounts which correlated roughly 
with the monomer band. This had been noticed 
previously and assigned to SDS-resistant assembly 
intermediates (26). Additionally, with GluA3 
samples, the densest fractions at the bottom of tube 
produced further intense diffuse smear-like 
immunoreactivity at very high molecular weight 
region (Fig. 6A). Due to this complex distribution 
of immunoreactivity we quantitated the 
immunoreactivity separately for the 110-kDa band 
(Fig. 6B) and for the entire sample lane (Fig. 6C). 
Inclusion of the diffuse immunostaining at ≥ 250-
kDa region did not significantly affect the overall 
result, but blurred the P1 peak of GluA3 protein 
because of the large amount of aggregates in the 
bottom fractions (Fig. 6C).  
In order to determine the major oligomeric 
state(s) of the receptor in P1 and P2, we subjected 
a sample of every other sucrose gradient fraction to 
BN-PAGE followed by immunoblotting. The 
samples were separated to four populations by rate 
of migration in the gel, which were assigned as 
aggregates (Ag), tetramers (T), dimers (D) and 
monomers (M) (Fig. 7A) as based on previous 
studies (24,27).  The highest-density sucrose 
fractions resolved into diffuse large-sized 
aggregates, whereas P1 and P2 peaks best 
coincided with the tetramer and dimer populations. 
Monomeric form was only (occasionally) seen in 
the post-P2 fractions of GluA2 protein (Fig. 7A). 
Quantitative analysis of the respective band 
intensities from five independent experiments 
revealed the strong presence of aggregates in 
GluA3 and dimers in GluA2 as the most striking 
differences between the subunits (Fig. 7B). Again, 
the double mutant GluA3 YR/AG showed 
intermediate behavior. Tetramers accounted for 
25-28 % of the total immunoreactivity in all three 
receptor variants. The ratio of dimers-to-tetramers 
was about 0.40 for GluA3 and 2.0 for GluA2 (Fig. 
7C), the predominance of dimers in GluA2 being 
in agreement with previous studies of GluA2 
biogenesis (26, 27). We also analyzed the Triton 
X-100 –extracts directly by BN-PAGE, without 
prior fractionation in sucrose gradient. The results 
confirm the strong presence of the dimeric species 
in wild-type GluA2i and its virtual absence in 
GluA3i. Moreover, the double mutants GluA2i 
AG/YR and GluA3i YR/AG showed banding 
patterns which were intermediate of their parental 
wild-type subunits (Fig. 7D). 
The sucrose density gradient fractionation 
and BN-PAGE analysis indicate that GluA3 
receptors have a much stronger tendency to form 
tetramers and larger oligomers/aggregates than 
GluA2 and this difference is largely but not totally 
eliminated by the YR/AG double mutation. 
 
DISCUSSION 
Native GluA3 subunits are predominantly 
associated with GluA2 (6,28) and coexpression 
with GluA2 (12; this study) rescues the otherwise 
poor surface expression of recombinant GluA3 
subunits (12,29), suggesting that GluA3 is an 
“obligatory heteromeric” subunit. Two amino acid 
residues, Y454 and R461, were previously 
identified as critical determinants of the poor 
surface expression of homomeric GluA3 receptors 
(12). Substituting the residues with their GluA2 
counterparts, alanine and glycine respectively, 
rescues the surface expression of GluA3 
homomers to GluA2 levels, and conversely, their 
incorporation to GluA2 leads to dramatic decrease 
in the transport to cell surface (12).  The location 
of these residues in the ligand-binding domain but 
outside of known subunit interfaces and the ligand 
binding cleft makes their striking effect on receptor 
transport enigmatic. Here, we wished to elucidate 
the biochemical mechanisms responsible for the 
inefficient expression of homomeric GluA3 
receptors on the plasma membrane by examining 
the differences in molecular properties between 
GluA2 and GluA3 receptors and their dependence 
on the YR/AG residues. 
Our analysis of full-length receptors 
identified detergent-solubility as a biochemical 
	 	 Aggregation of GluA3 subunits 	
8		
property which clearly distinguished between 
GluA2 and GluA3 and was strongly dependent on 
the YR/AG residues. The majority of GluA2 
expressed in HEK293 cells was soluble in Triton 
X-100, whereas most of immunoreactive GluA3 
appeared as insoluble aggregates. Double 
mutations at YR/AG positions shifted the 
solubility of GluA2 or GluA3 towards the other 
subunit, indicating that Y454 and R461 promote 
aggregation. To find out if this is caused by poor 
folding or instability of GluA3 LBD, we expressed 
wild-type and mutated GluA2 and GluA3 LBDs as 
soluble fusion proteins. The secretion efficiencies 
of GluA2 and GluA3 LBDs in HEK293 cells 
closely mimicked the transport phenotypes of the 
cognate membrane-bound receptors, and were 
completely reversed by mutations at the YR/AG 
residues. Spectroscopic analysis of the unfolding 
of purified LBDs, purified from E.coli expression, 
yielded classical cooperative unfolding curves for 
both GluA2 and GluA3. Unexpectedly, GluA3 
LBD appeared more stable than GluA2 against 
both urea-induced and thermal denaturation, but 
this effect was unrelated to the trafficking 
difference as the GluA3 YR/AG double mutant 
showed similar stability to wild-type GluA3. These 
findings suggest that the aggregation-promoting 
effect of Y454/R461 residues is not caused by 
unstable fold of GluA3 LBD.  Of note, the 
occurrence of thermal denaturation of ligand-free 
LBDs at or near physiological temperature, 
together with the strong stabilizing effect by 
glutamate, are consistent with the emerging 
concept that glutamate in the ER acts as a 
physiological chaperone in AMPA receptor folding 
(23,24,30-32).  
Analysis of the detergent-soluble 
receptors, assumed to represent the properly folded 
protein, by sucrose density gradient centrifugation 
and blue native gel electrophoresis revealed 
differences in the oligomeric status of GluA2 and 
GluA3 proteins. Major immunoreactive peaks 
from sedimentation in density gradients resolved in 
higher oligomers/microaggregates, tetramers and 
dimers. Consistent with aggregation in the 
macroscopic scale, over half of immunoreactive 
GluA3 existed as microaggregates or complexes 
larger than tetramers. GluA2 and GluA3 
preparations contained tetramers at similar relative 
amounts, but the proportion of dimers was much 
higher for GluA2, in agreement with an earlier 
study (27). The double mutation YR-to-AG shifted 
the hydrodynamic behavior and dimer-to-tetramer 
ratio of GluA3 towards GluA2, albeit not 
completely. The lower dimer-to-tetramer ratio 
(0.4:1) suggests that GluA3 tetramers are more 
stable/less dynamic than those of GluA2 (2:1). 
Considering this fact with the failure of stargazin, 
which associates selectively with tetrameric 
AMPA receptors in the ER (33,34), to significantly 
promote GluA3 surface expression, we speculate 
that the (majority of) GluA3 tetramers do not 
represent the native conformation but some 
incompletely matured intermediate.  
Our study shows that homomeric GluA3 
receptors are prone to aggregation at both 
molecular and macroscopic levels, and that this 
tendency is strongly linked to the two residues 
which determine the intracellular retention of 
GluA3 homomers. In an attempt to provide a 
mechanistic explanation for these findings, we 
present a tentative model (Fig. 8) which 
accommodates our experimental results with the 
body of current research literature on AMPA 
receptor assembly (for reviews, see Refs. 35-38). 
The crystal structure of GluA2 tetramers shows 
that the LBDs and NTDs are organized as pairs of 
dimers, one subunit in each pair occupying a 
proximal and the other a distal position around the 
central axis, whereas the membrane-associated 
regions are arranged around the ion channel in a 
four-fold symmetrical fashion (10). Based on the 
GluA2 tetramer structure, the critical GluA3 
residues Y454 and R461 would  point  outwards 
from the tetramer in the proximal LBDs and 
inwards in the distal LBDs (12). Heteromeric 
AMPA receptors are believed to have a 2:2 
stoichiometry with the subunits adopting an 
alternating arrangement (“1-2-1-2”; Refs. 3,39), 
which in the case of GluA2/3 is ensured by 
preferred formation of NTD heterodimers 
(11,35,40). Thus, depending on whether the GluA3 
subunits would favor the proximal or the distal 
positions in the LBD layer, the critical residues 
would be either exposed on the tetramer´s  outer 
surface or masked inside. The rescue of plasma 
membrane expression and decrease of GluA3 
aggregation would then arise from preferential 
adaptation of GluA3 LBDs of one of the two 
alternative orientations upon coassembly with 
GluA2. Whether the outer or inner orientation is 
detrimental to proper maturation and surface 
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expression is presently unclear. However, we favor 
a scanario in which the outward orientation of 
Y454/R461 residues would lead  to aggregation 
through lateral interactions, as we suggested earlier 
(12) based on the location of homologous GluA2 
residues at an intermolecular interface present in 
an LBD crystal structure (19,20). Therefore, we 
propose that upon heteromeric assembly with 
GluA2, GluA3 LBDs would strongly favor the 
distal positions (as in heteromer 2; Fig. 8B). In 
contrast, in GluA3 homomers (and in the 
unfavored heteromer 1-like GluA2/3 receptors), 
the exposed Y454/R461 residues would drive the 
formation of higher oligomers, impeding 
maturation and transport to cell surface (Fig. 8C). 
Similarly, the poor secretion of GluA3 LBD would 
be caused by a tendency to form head-to-tail 
intermolecular contacts, which may interfere with 
efficient secretion. The other scenario which gives 
the critical role to the inwardly oriented residues, is 
more difficult to reconcile with the LBD data.    
To summarize, one of the two orientations 
of GluA3 residues Y454 and R461 promotes 
aggregation and formation of transport-
incompetent tetramers, resulting in intracellular 
retention of homomeric GluA3 receptors. 
Coassembly with GluA2 leads to elimination of the 
deleterious orientation allowing the forward 
trafficking of GluA2/3 heteromers to the cell 
surface. In conclusion, our results demonstrate that 
propensity to aggregate can explain subunit-
dependent differences in surface expression of 
AMPA receptors. Interestingly, the critical 
determinant for the poor surface transport of 
homomeric GluA1 and GluA4 flop receptors, a 
single Leu/Val residue, is positioned quite close to  
the Y454 and R461 studied in GluR3 (13, 20). 
Future studies will reveal whether the mechanisms 
identified here for GluA3 will also apply to the 
poor trafficking of flop variants. 
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FIGURE LEGENDS  
 
Figure 1. GluA2 subunit rescues surface expression of GluA3. (A) AMPA subunits GluA2-flip 
(GluA2i) and GluA3-flip (GluA3i) were either N-terminally Flag-tagged or C-terminally GFP-tagged and 
expressed in HEK293 cells, as indicated above the panels. Cells were surface biotinylated and cell extracts 
subjected to streptavidin pulldown (surface). Immunoblots were probed with anti-GFP. Endogenous 
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GAPDH protein used as a loading control. The presence of C-terminal GFP did not alter the surface 
trafficking phenotypes of GluA2 and GluA3. (B) GluA3i-GFP was co-expressed with GluA3i, GluA2i, 
GluA2-flop (GluA2o) or with the A451Y/G458R double mutant of GluA2-flip or -flop as indicated and 
subjected to biotinylation assay as above. Antibodies used for blotting are indicated on the right. Note that 
anti-GluA2/3 recognizes both GluA2 and GluA3 C-termini, but has weaker binding to GluA3. (C) 
Quantification of GluA3-GFP cell surface expression following co-expression with indicated proteins. 
Anti-GFP IgG immunoblot signals were normalized to the co-expressed GluA3i. Bars show mean ± SEM,  
n=7-14.  Statistical analysis of the co-expressed GluA3i-GFP surface expression was determined by one-
way ANOVA, p=0.006; Bonferroni’s multiple comparison post-test gave the following p values: F-A3i vs. 
F-A2i, p<0.01 and F-A2i vs. F-A2(AG/YR) p<0.05, all others p>0.05. Dunnett’s multiple comparison post 
test gave the following p values: F-A3i vs. F-A2i, p<0.01 and F-A3i vs. F-A2o, p<0.05, all others p>0.05. 
(D) AMPA receptor subunits GluA2i and GluA3i were N-terminally Flag (F) or Myc (M) -tagged and co-
expressed in HEK293 cells, as indicated above the panels. Receptors were immunoprecipitated (IP) with 
either anti-Flag or anti-myc antibodies and immunoblotted as indicated below.  
 
Figure 2. Stargazin interacts with GluA3 but does not promote its transport to cell surface. (A) 
Immunoblot of biotinylated surface GluA3 receptors expressed alone or with stargazin as detected by anti-
GluA2/3 IgG (upper panel). The presence or absence of stargazin is shown in the middle panel, blotted 
with anti-stargazin serum. Lower panel shows endogenous GAPDH protein as a loading control. (B) 
Quantification of GluA3i ± stargazin surface expression immunoblots; GluA3i + stargazin signal was 
normalized to GluA3 expression alone.  Bars show mean ± SEM, n=6. Statistical analysis by paired, one-
tailed t-test gave p=0.0762  indicating no significant statistical difference. (C) Immunoblot showing 
association between GluA2i or GluA3i and stargazin. Expressed AMPA receptors were 
immunopreciptiated by anti-Flag antibody and the immunoprecipitates were probed for the associated 
stargazin (lower panel). The anti-stargazin signal ratio GluA3i+Stg/GluA2i+Stg was 1.23±0.239 (SEM), 
n=7. One sample t-test with control value set to one gave p=0.38, indicating no statistically significant 
difference. (D) Summed electrophysiology data from whole-cell patch-clamp recordings of HEK293 cells 
expressing GluA3i either alone (n=8) or with stargazin (n=9) and following application of 10 mM L-
glutamate. The bars show mean ± SEM for whole-cell peak currents. Statistical analysis by unpaired one-
tailed t-test gave p=0.0764 indicating no significant difference. (E) Comparison of tau of desensitization 
values from whole-cell patch-clamp recordings of HEK293 expressing either GluA3 alone (n=5) or with 
stargazin (n=8). Bars indicate mean ± SEM. Statistical analysis by unpaired one-tailed t-test gave 
p=0.0004, indicating stargazin has a significant effect on the desensitization kinetics of GluA3 channels. 
 
Figure 3. Ligand binding domain secretion mimics the cognate full-length receptor trafficking 
phenotype 
(A) Schematic structure of the mature GluA3i LBD polypeptide expressed in mammalian cells. The 
included S1 and S2 residues are indicated, as are the point mutation sites; the S1 and S2 domains are 
joined by a flexible 13 residue linker with the sequence STEGEVNAEEEGF (13, 41). For efficient 
secretion, the expression plasmid encoded a viral signal peptide (MTILCWLALLSTLTAVNA) placed N-
terminally from the Flag epitope (41). The numbering is from rat GluA3, Uniprot sequence P19492 (12). 
All LBD constructs for mammalian expression encode an N-terminal Flag tag and C-terminal Myc tag. 
(B) Representative immunoblots showing expression of GluA2i and GluA3i LBD proteins from 
transfected HEK293 cells, both ‘wild-type’ and point-mutated versions (upper panels, anti-Myc IgG). 
Left-hand panels show protein expression in cell extracts; right-hand panel shows expression of constructs 
in cell media following secretion. Endogenous GAPDH protein is shown as a loading control. (C) 
Quantitation of LBD constructs expression from cell extract (solid shading) and media (hatched shading). 
Immunoblot signals were normalized to GluA2 LBD expression. Bars show mean ± SEM,  n=4-11. For 
cell extract samples one-way ANOVA gave  p=0.0006 and for media samples one-way ANOVA 
p<0.0001. Significance determined by Dunnett’s multiple comparison to GluA2i LBD as control is shown, 
** indicates p<0.01. 
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Figure 4. Instability of the LBD does not explain the poor trafficking of GluA3 
(A) Schematic structure of the GluA3i LBD polypeptide expressed intracellularly in bacterial cells. The 
included S1 and S2 residues are indicated, as are point mutation sites; the S1 and S2 domains are joined 
by a two amino acid linker. All LBD constructs for bacterial expression have a C-terminal 6xHis tag for 
purification. (B) Typical graphs for urea denaturation of purified GluA2i and GluA3i LBD proteins 
following expression and purification from bacteria. Measurement was by intrinsic fluorescence 
spectroscopy and LBDs were denatured in absence or presence of 10 mM L-glutamate. (C) A scatter plot 
of measured EC50 values for  urea denaturation of GluA2i and GluA3i LBDs with or without ligand. 
Points indicate individual values and line is mean. Statistical analysis by one-way ANOVA gave 
p<0.0001. Bonferroni’s multiple comparison test indicated a significance effect (p<0.001) for the presence 
of L-glutamate for both LBDs; it also indicated GluA3i LBD was significantly more stable than A2i LBD 
both without L-Glu (p<0.05) and with L-Glu (p<0.01). (D) Best fit non-linear plots of thermal denaturation 
of purified GluA2i, A3i and A3i(YR/AG) LBD proteins. Measurement was by CD spectroscopy. LBDs 
with or without L-glutamate.  GluA2i is shown in blue, GluA3i in red, and A3i(YR/AG) in grey. Statistical 
analysis by paired t test of measured Tm in the presence or absence of L-Glu indicates a significantly 
stabilizing effect of glutamate (p= 0.0038). In the absence of L-glutamate symbols and lines are solid; with 
L-glutamate symbols and lines are open or dashed respectively. 
 
Figure 5. GluA3 is more resistant to solubilization than GluA2 
(A) Typical immunoblot of full length N-terminally Flag-tagged GluA2i and GluA3i expressed in 
HEK293 cells and following 1% Triton X-100 extraction and ultracentrifugation; soluble refers to 
supernatant sample and insoluble to the resultant pellet. The blot was probed with anti-Flag antibody. (B) 
Quantification of signal measured from such immunoblots, adjusted for the difference in final sample 
volume and expressed as the percentage of soluble receptor. Bars show mean ± SEM for n=13 
independent experiments. Statistical analysis by paired, one-tailed student t-test gave a p=0.0004. (C) 
Immunoblot showing increased sequestering of NMDA receptor GluN1 (N1) subunit in insoluble fraction 
when co-expressed with GluA3i in HEK293 cells. (D) Quantification of GluN1 signal from such 
immunoblots and expressed as ratio GluN1+A3i/GluN1+GFP for both soluble and insoluble fraction. Bars 
show mean ± SEM for n=3 independent experiments. Analysis by one sample t-test with control value set 
to one gave p=0.127 for soluble fraction and p=0.012 for insoluble fraction. (E) Typical immunoblot of N-
terminal Flag-tagged GluA2i and GluA3i and respective mutants expressed in HEK293 cells and 
following 1% Triton X-100 extraction and ultracentrifugation. Upper panel shows receptor signal from 
soluble fraction and the lower panel shows GAPDH loading control from the same blot. (F) 
Quantification of signal measured from such immunoblots and expressed as a ratio of soluble receptor to 
GAPDH. Bars show mean ± SEM for n=4 independent experiments. (G) Typical immunoblot of N-
terminal Flag-tagged GluA2o and GluA3o and respective mutants expressed in HEK293 cells and 
following 1% Triton X-100 extraction and ultracentrifugation. Upper panel shows receptor signal from 
soluble fraction and the lower panel shows GAPDH loading control from the same blot. (H) 
Quantification of signal measured from such immunoblots and expressed as a ratio of soluble receptor to 
GAPDH. Bars show mean ± SEM for n=4 independent experiments. For both F and G, statistical analysis 
by one way ANOVA gave an overall p<0.0001, Dunnett’s comparison to control (GluA3) gave: A3 vs 
A2, p<0.01; A3 vs A2(AG/YR), p>0.05; A3 vs A3(YR/AG) p<0.01. (I) Immunoblot of GRP78 of Triton 
X-100 –soluble extracts prepared from GluA2i or GluA3i expressing HEK293 cells, untransfected cells, 
or from untransfected cells with or without tunicamycin (2 µg/ml) treatment as indicated. Upper panel: 
anti-GRP78 signal; lower panel: anti-Flag signal. (J) Coimmunoprecipitation of GluA2i and GluA3i with 
GRP78. Anti-GRP78 and anti-Flag immunoblots are shown for the Triton X-100 extracts (input) and anti-
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Figure 6. Sucrose gradient analysis reveals assembly differences between the receptors   
(A) Typical SDS-PAGE immunoblots of fractions following sucrose gradient centrifugation of Triton X-
100 extracts from HEK293 cells expressing N-terminally Flag-tagged GluA3, GluA3 (YR/AG) and 
GluA2. Fraction 1 is densest and fraction 23 is lightest, as indicated by bar underneath. The subunit 
monomer signals are indicated by an arrowhead. A band at 250 kD and a higher aggregate smear is seen 
for all receptors; however, the fraction location and intensity varies.  All blots were probed with anti-Flag 
antibody and the molecular weight markers are indicated. (B and C) Signal intensity profiles derived from 
the immunoblots shown. (B) shows the signal profile from the monomer band in each fraction, where [!!/ !1 − !24] ∗ 100. (C) shows the signal profile from entire detected signal (monomer, oligomer 
and aggregate) of each fraction. Peak 1 (P1) corresponds to fractions F5-8 and peak 2 (P2) corresponds to 
fractions F12-15. 
 
Figure 7. BN-PAGE analysis reveals oligomeric steady-state differences between the receptors   
(A) Typical BN-PAGE immunoblots of every other fraction following sucrose gradient centrifugation of 
Triton-X 100 extracts from HEK293 cells expressing N-terminally Flag-tagged GluA3, GluA3 (YR/AG) 
and GluA2 (same samples as shown in SDS-PAGE immunoblots). Signals corresponding to aggregate 
(Ag), tetramer (T), dimer (D) and monomer (M) species are indicated. Boxes in the middle panel highlight 
the oligomeric state and regions used for the percentage analysis. Fraction numbers are indicated above 
and below, and P1 and P2 indicate the analyzed fractions from the peaks seen in the Figure 6 SDS-PAGE 
analysis. (B) Summary graph of the oligomeric state for each receptor. Bars correspond to mean ± SEM, 
n=5. Statistical analysis by two-way ANOVA gave an overall p<0.0001. Bonferroni’s post-test 
comparison of oligomeric states between receptors indicated significant difference in aggregate and dimer 
states between GluA2 vs GluA3 (p<0.001 for both) and GluA2 vs A3 (YR/AG) (p<0.01 for both). 
However, the GluA3 wild-type vs. mutant did not show any significant difference for any oligomeric state. 
Notably, there was no significant difference in tetramer or monomer percentage between any of the 
receptors. (C) Graph highlighting the variation in dimer: tetramer ratio between the receptors. Bars 
correspond to mean ± SEM, n = 5. Statistical analysis by one-way ANOVA gave an overall p = 0.0342. 
Bonferroni’s post-test comparison indicated significant difference in between GluA2 vs GluA3 (p<0.05) 
but not for any other comparison. (D) BN-PAGE immunoblots (anti-Flag) of crude Triton X-100 extracts 
prepared from HEK293 cells expressing Flag-tagged GluA2i, GluA3i, GluA2i(AG/YR) or 
GluA3i(YR/AG). Bots from two independent transfections are shown. 
 
Figure 8. GluA3 -containing receptor assembly and trafficking 
(A) The location of GluA2 residues A451 and G458, corresponding to GluA3 Y454 and R461, in GluA2 
tetramer model (Protein Data bank code 3kg2 ; Ref.10). The proximal and distal LBDs chains (relative to 
the two-fold axis of symmetry) are colored blue and green, respectively, and the A451 and G458 residues 
are shown as red van der Waals spheres. The upper models shows the LBD layer from above, whereas the 
lower model shows the tetramer from the side with NTD layer in light grey. Note the peripheral position 
of the residues in the proximal and central location in the distal LBDs. (B) Simplified schematic of LBD 
organization in GluA3 homomers and in GluA2/3 heteromers. The proximal LBDs are shown as circles 
and the distal LBDs as squares. GluA3 residues Y454 and R461 are shown as black circles. GluA3 and 
GluA2 subunits are colored red and blue, respectively. Note that in GluA2/3 heteromers, Y454/R461 
residues can face either outwards (heteromer 1) or inwards (heteromer 2). (C) Schematic of major 
assembly and transport pathways of homomeric GluA3 and heteromeric GluA2/3 receptors. Following 
tetramer assembly, the transport -competent heteromers (left) undergo maturation, leave the ER, and 
traffic to the plasma membrane. GluA3 homomers predominantly give rise to aggregation via molecular 
interactions involving the proximal LBDs and remain stuck within the ER. (D) The primary sequence 
surrounding the identified residues of interest (shown in blue and red) within the S1 domain in the four 
AMPA receptor subunits. Asterisks indicate identical residues; double dots strong similarity; single dot 
weak similarity. 
 




Table 1. Stability of bacterially expressed LBD against urea-induced and thermal denaturation.  
 GluA2 GluA3 GluA3(YR/AG) 
EC50 for urea 
(M) (mean ± 
SEM) 
-  L-Glu 1.46 ± 0.17 2.23 ± 0.04 N.D. 
+ L-Glu 
(10 mM) 
4.05 ± 0.17 4.96 ± 0.13 N.D. 
Tm (°C)  
(mean; 95 % 
confidence 
interval) 




51.37 (50.59-52.25) 55.57 (54.91-56.22) 55.48 (55.12-55.84) 
N.D. is not determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 








